PDSB RSI Chart
Last 7 days
-0.6%
Last 30 days
28.3%
Last 90 days
-35.4%
Trailing 12 Months
-52.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2018 | 851.3K | 944.4K | 917.6K | 871.9K |
2017 | 265.7K | 385.3K | 543.3K | 700.9K |
2016 | 51.8K | 99.8K | 154.5K | 212.3K |
2015 | 0 | 5.0K | 7.0K | 9.1K |
2014 | 0 | 0 | 3.4K | 2.9K |
2013 | 0 | 0 | 0 | 4.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 02, 2022 | bedu-addo frank | acquired | 1,442,340 | 6.57 | 219,535 | president/ceo |
Dec 02, 2022 | bedu-addo frank | sold (taxes) | -1,713,300 | 9.78 | -175,184 | president/ceo |
Dec 13, 2021 | hill matthew c | bought | 900 | 9.00 | 100 | chief financial officer |
Dec 13, 2021 | hill matthew c | bought | 26,060 | 8.98621 | 2,900 | chief financial officer |
Jun 16, 2021 | bloomquist delyle w | bought | 98,778 | 9.8778 | 10,000 | - |
Jun 16, 2021 | bloomquist delyle w | acquired | 17,790 | 5.99 | 2,970 | - |
Jun 15, 2021 | van voorhees seth | bought | 150,000 | 8.5 | 17,647 | chief financial officer |
Jun 15, 2021 | glover steve c | bought | 49,997 | 8.5 | 5,882 | - |
Jun 15, 2021 | freitag gregory gene | bought | 49,997 | 8.5 | 5,882 | - |
Which funds bought or sold PDSB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 269 | 196,905 | 298,104 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.16 | -11,602 | 11,270 | -% |
May 15, 2024 | Corton Capital Inc. | sold off | -100 | -75,296 | - | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -73.23 | -44,000 | 12,000 | -% |
May 15, 2024 | Voya Investment Management LLC | sold off | -100 | -59,824 | - | -% |
May 15, 2024 | Iron Gate Global Advisors LLC | unchanged | - | -77,995 | 294,835 | 0.05% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | sold off | -100 | -1,988,000 | - | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | sold off | -100 | -63,203 | - | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 163,235 | 163,235 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -201,663 | - | -% |
Unveiling PDS Biotechnology Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to PDS Biotechnology Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
PDS Biotechnology Corp News
Income Statement (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2014Q4 | 2014Q3 | 2013Q4 |
Revenue | -6.1% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
Operating Expenses | 129.8% | 2.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 159.1% | 1.00 | 1.00 | 0.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | 37.5% | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -5.5% | 890* | 942* | 804* | 959* | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -155.8% | -1.82 | -0.71 | -0.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 16.2% | 69.00 | 59.00 | 57.00 | 64.00 | 68.00 | 77.00 | 75.00 | 56.00 | 61.00 | 67.00 | 72.00 | 77.00 | 28.00 | 31.00 | 34.00 | 20.00 | 24.00 | 14.00 | 19.00 | 26.00 | 31.00 |
Current Assets | 16.3% | 69.00 | 59.00 | 57.00 | 63.00 | 68.00 | 76.00 | 74.00 | 56.00 | 61.00 | 67.00 | 71.00 | 77.00 | 27.00 | 30.00 | 34.00 | 19.00 | 24.00 | 14.00 | 18.00 | 23.00 | 28.00 |
Cash Equivalents | 17.8% | 67.00 | 57.00 | 54.00 | 61.00 | 65.00 | 74.00 | 72.00 | 53.00 | 59.00 | 65.00 | 70.00 | 75.00 | 25.00 | 29.00 | 33.00 | 17.00 | 21.00 | 12.00 | 17.00 | 22.00 | 27.00 |
Net PPE | -3.5% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | 86* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -4.3% | 32.00 | 33.00 | 33.00 | 31.00 | 27.00 | 33.00 | 28.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | - | - | 4.00 | 3.00 | - | - | - |
Current Liabilities | 10.5% | 15.00 | 14.00 | 9.00 | 8.00 | 4.00 | 10.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 6.00 |
Shareholder's Equity | 42.3% | 37.00 | 26.00 | 24.00 | 32.00 | 41.00 | 44.00 | 47.00 | 51.00 | 56.00 | 63.00 | 68.00 | 73.00 | 24.00 | 27.00 | 31.00 | 17.00 | 20.00 | 12.00 | 16.00 | 21.00 | 24.00 |
Retained Earnings | -7.3% | -155 | -144 | -133 | -122 | -111 | -101 | -82.42 | -75.00 | -69.18 | -60.70 | -54.38 | -47.42 | -46.83 | -43.79 | -39.76 | -35.85 | -32.92 | -28.94 | -23.83 | -18.08 | -14.20 |
Additional Paid-In Capital | 12.7% | 192 | 171 | 158 | 155 | 152 | 146 | 129 | 126 | 125 | 124 | 122 | 120 | 71.00 | 71.00 | 71.00 | 53.00 | 53.00 | 41.00 | 39.00 | 39.00 | 39.00 |
Shares Outstanding | 10.8% | 37.00 | 33.00 | 31.00 | 31.00 | 31.00 | 30.00 | 28.00 | 28.00 | 26.00 | 28.00 | 25.00 | 23.00 | 22.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 148 | - | - | - | 98.00 | - | - | - | 340 | - | - | - | 23.00 | - | - | - | 18.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -17.5% | -9,938 | -8,457 | -7,175 | -4,814 | -13,188 | -7,528 | -5,892 | -5,918 | -6,369 | -4,501 | -5,128 | 946 | -3,802 | -4,629 | -1,252 | -4,103 | -3,164 | -5,519 | -4,327 | -4,858 | -3,367 |
Share Based Compensation | 20.3% | 1,630 | 1,355 | 2,074 | 2,106 | 2,080 | 1,374 | 1,344 | 1,349 | 1,129 | 1,673 | 1,702 | 442 | 258 | 131 | 130 | 46.00 | 125 | 245 | 120 | 19.00 | 2,755 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 275 | - | - | 29,107 |
Cashflow From Financing | 85.9% | 20,012 | 10,766 | 802 | 240 | 4,568 | 9,707 | 24,551 | 22.00 | 7.00 | 13* | 124 | 48,766 | - | - | 17,787 | - | 12,040 | - | - | - | 750 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development expenses | $ 6,704,164 | $ 5,843,686 |
General and administrative expenses | 3,393,463 | 3,578,728 |
Total operating expenses | 10,097,627 | 9,422,414 |
Loss from operations | (10,097,627) | (9,422,414) |
Interest income (expenses), net | ||
Interest income | 668,895 | 729,341 |
Interest expense | (1,174,745) | (966,845) |
Interest income (expense), net | (505,850) | (237,504) |
Net loss | (10,603,477) | (9,659,918) |
Comprehensive loss | $ (10,603,477) | $ (9,659,918) |
Per share information: | ||
Net loss per share, basic (in dollars per share) | $ (0.3) | $ (0.32) |
Net loss per share, diluted (in dollars per share) | $ (0.3) | $ (0.32) |
Weighted average common shares outstanding, basic (in shares) | 34,815,870 | 30,428,053 |
Weighted average common shares outstanding, diluted (in shares) | 34,815,870 | 30,428,053 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 66,634,417 | $ 56,560,517 |
Prepaid expenses and other assets | 2,051,348 | 2,494,558 |
Total current assets | 68,685,765 | 59,055,075 |
Property and equipment, net | 129,398 | 134,132 |
Financing lease right-to-use assets | 191,203 | 200,873 |
Total assets | 69,006,366 | 59,390,080 |
Current liabilities: | ||
Accounts payable | 6,000,831 | 6,982,824 |
Accrued expenses | 1,714,111 | 2,424,692 |
Note payable - short term | 7,291,667 | 4,166,667 |
Financing lease obligation-short term | 57,081 | 55,794 |
Total current liabilities | 15,063,690 | 13,629,977 |
Noncurrent liabilities: | ||
Notes payable, net of debt discount | 16,651,420 | 19,506,183 |
Financing lease obligation-long term | 108,211 | 122,973 |
Total liabilities | 31,823,321 | 33,259,133 |
STOCKHOLDERS' EQUITY | ||
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2024 and December 31, 2023, 36,679,275 shares and 33,094,521 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 12,104 | 10,921 |
Additional paid-in capital | 192,275,033 | 170,620,641 |
Accumulated deficit | (155,104,092) | (144,500,615) |
Total stockholders' equity | 37,183,045 | 26,130,947 |
Total liabilities and stockholders' equity | $ 69,006,366 | $ 59,390,080 |